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Cancer is characterized by uncontrolled and 
invasive growth of cells. These cells may spread to 
other parts of the body, and this is called metastasis 
(1). Tumorigenesis is a multistep process that 
requires several integrated events to allow a cell to 
grow rapidly without the input of extraneous 
growth-stimulating signals, and to overcome 
growth-inhibitory signals and host immune 
responses. Tumour cells must also be able to 
circumvent APOPTOSIS, replicate indefinitely and 
sustain growth and survival by maintaining a 
sustainable oxygen and nutrient supply. Mutations 
 
Prostate cancer is the third major cause of death in men 
worldwide after lung cancer, cardiovascular disease and is 
known in two decades. Since 1987, the first treatment for 
prostate cancer was initiated in the wake of the global health 
So far safer and effective methods to treat this life threatening 
condition is better. During the past two decades' scientists to 
develop drugs targeted therapies in cancer research priorities 
were. These therapies primarily based on a specific antigen in 
tumor tissues will be deployed. Prostate cancer-specific 
antigens of the most valuable PSMA (Prostate spacific 
membrane antygen) is. In this study, to evaluate the PSMA 
binding affinity ligands can be connected to evaluate and 
recommend the best ligand for use in targeted drugs.  
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that result in constitutive activation of oncogenes 
or functional inactivation of Tumour-Suppressor 
Genes are important tumorigenic events. Although 
these mutations can affect several cellular 
pathways in the absence of de novo protein 
synthesis, aberrant gene expression — which is 
often downstream of these mutations — also has 
an important role in tumour initiation and 
progression. In addition,mutations within gene 
promoter or enhancer regions, or epigenetic 
changes, can induce abnormal expression of genes 
that regulate cellular differentiation, the cell cycle 
and apoptosis, thereby enhancing the potential for 
cellular transformation. Moreover, aberrant 
transcription of the genes that are needed to 
initiate the host antitumour immune response and 
induce neovasculature can result in tumour 
immune escape and angiogenesis — events that 
are essential for cancer progression (2).The 
hallmarks of cancer are properties such as 
constitutive proliferative signaling, de-regulation 
of cellular energetics, resistance to cell death, 
evasion of growth suppressors, avoidance of 
immune destruction, enabling of replicative 
immortality, tumor-promoting inflammation, 
activation of invasion and metastasis, genomic 
instability and mutation, as well as induction of 
tumor angiogenesis (3). Prostate specific 
membrane antigen (PSMA), is a unique membrane 
bound glycoprotein, which is overexpressed 
manifold on prostate cancer as well as 
neovasculature of most of the solid tumors, but not 
in the vasculature of the normal tissues. This 
unique expression of PSMA makes it an important 
marker as well as a large extracellular target of 
imaging agents. PSMA can serve as target for 
delivery of therapeutic agents such as cytotoxins 
or radionuclides. PSMA has two unique enzymatic 
functions, folate hydrolase and NAALADase and 
found to be recycled like other membrane bound 
receptors through clathrin coated pits. These 
capabilities to target PSMA for prostate cancer-
specific therapy has become. PSMA is a type II 
membrane glycoprotein, Mr 100,000 dalton with 
an intracellular segment (amino acids 1–18), a 
transmembrane domain (amino acids 19–43), and 
an extensive extracellular domain (amino acids 44
–750). Human PSMA gene was first cloned in Dr. 
Heston’s laboratory from LNCaP cells and was 
found to be located in chromosome 11p11-12, 
which encodes for PSMA transcript expression in 
prostate. Another gene, highly homologous to 
PSMA was found to be located at the loci 11q14.3 
is called PSM-like. The PSM like gene is 
expressed in different tissues, such as kidney and 
liver, but not in prostate. These capabilities to 
target PSMA for prostate cancer-specific therapy 
has become. This should be connected to different 
ligands to the receptor cells. These ligands can act 
as carriers of drugs to cancer cells and also help to 
deliver the drug into the target cell (4-6). 
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Material and method: 
Sequence extraction: To study the receptor ligand 
interactions and gene-ligand protein sequence will 
be needed. Refer to the database to obtain this 
sequence with NCBI Gene database and search 
can be achieved PSMA protein structural 
sequence. The conventional structure of a protein 
called PSMA FOLH1 in these databases is 
retrieved. 
Ligand assays: 
To determine the PSMA protein ligands can be 
connected to refer to the database String. The 
database can also be connected to a particular 
receptor called ligands, to study the biochemical 
properties and their performance in vivo as well. 
3D refinement: 
Many three-dimensional structure of molecules 
extracted from the site String Swiss model be 
derived from the database. In fact, the same 
structures polypeptide sequence and correspond to 
90% will be suitable for us as structures. Due to 
the PDB code, the structure of the ligands in the 
base string to three-dimensional structure of the 
format PDB achieved, but many ligands three-
dimensional structure not have a clear and we 
obtain three-dimensional structure they need to use 
the software Modeler we have. 
Docking:  
PSMA binding affinity between ligands and 
receptors to study the exact process used Dokhing. 
In this method, the receptor binding epitopes 
between the ligand and receptor binding specified 
then the various states will be investigated. 
Finally, it is possible for researchers to be the best 
and truest obtain a connection between the ligand 
and antigen. Also according to the energy level 
and stability of the connection can be correct 
comparison between different ligands to determine 
the best bridging ligand did. There Doking 
different software for online and offline software 
Molegro were used in this study. 
Results: 
The molecular pathway of antigens 
In addition to its role as a tumor marker, PSMA 
contains a binuclear zinc site and is active as a 
glutamate carboxypeptidase, catalyzing the 
hydrolytic cleavage of α- or γ-linked glutamates 
from peptides or small molecules. Its substrates 
include poly-γ-glutamated folates, which are 
essential nutrients, and the poly-γ-glutamated form 
of the anticancer drug methotrexate, in which case 
cleavage renders it less efficacious. The enzymatic 
activity of PSMA can be exploited for the design 
of prodrugs, in which an inactive glutamated form 
of the drug is selectively cleaved and thereby 
activated only at cells that express PSMA.  
PSMA also cleaves and inactivates the abundant 
neuropeptide N-acetyl-L-aspartyl-L-glutamate (α-
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-NAAG), which is an inhibitor of the NMDA 
ionotropic receptor and an agonist of the type II 
metabotropic glutamate receptor subtype 3. A 
breakdown of the regulation of glutamatergic 
neurotransmission by α-NAAG is implicated in 
schizophrenia, seizure disorders, Alzheimer's 
disease, Huntington's disease, and amyotrophic 
lateral sclerosis. Thus, inhibition of PSMA 
potentially confers neuroprotection both by 
reducing glutamate and increasing α-NAAG.  
Indeed, the subnanomolar inhibitor 2-
(phosphonomethyl) pentanedioc acid has been 
shown to provide neuroprotection in cell culture 
and/or animal models of ischemia, diabetic 
neuropathy, drug abuse, chronic pain, and 
amyotrophic lateral sclerosis. 
3D characterization of Antigen  
Overall Structure of PSMA. The structure reveals 
a symmetric dimer with each polypeptide chain 
containing three domains analogous to the three 
TfR1 domains: a protease domain (residues 56-
116 and 352-591), an apical domain (residues 117-
351), and a helical domain (residues 592-750) 
(Fig. 1 and Table 1). A large cavity (≈1,100 Å2) at 
the interface between the three domains includes a 
binuclear zinc site and predominantly polar 
residues (66% of 70 residues) (supporting 
information). The observation of two zinc ions 
and conservation of many of the cavity-forming 
residues among PSMA orthologs and homologs 
identify the cavity as the substrate-binding site.  
Vol. 3, No. 4, Dec, 2017 
Rastegar-Moghadam et al., 2017. The Cancer Press, 3(4): 136-145                                                                                                     139    
Fig.1. Structural comparison of PSMA and related proteins. The common fold of the protease or protease-like domain consists of a cen-
tral seven- to eight-stranded mixed β-sheet and 6-11 flanking α-helices. Ribbon diagrams of side and top view of PSMA (A), side and top 
view of TfR1 (PDB ID code 1CX8) (B), AAP (PDB ID code 1RTQ) (C), CPG2 (PDB ID code 1CG2) (D). The protease (or protease-
like) domains are shown in blue, the apical domains of PSMA and TfR1 in green, the helical domains in red, and the CPG2 dimerization 
domain in pink. Water molecules are red, zinc ions are orange, zinc-binding residues are yellow sticks, and carbohydrate residues are 
shown in a color-coded ball-and-stick representation. Representative substrates are shown below the appropriate molecule. R1 = OH or 
NH2, and R2 = H or CH3 for folate and methotrexate, respectively. Note: A mono-γ-glutamated folate is shown for clarity; in poly-γ-
glutamated folate/methotrexate, the additional glutamates (up to seven) are attached to the glutamate shown via a γ-peptide linkage. 
www.thecancerpress.com 
www.imaqpress.com  
Corresponding ligands of the antigen  
Using the Software string of 10 ligands can be 
connected to the PSMA antigen obvious that this 
between us three ligands AIMP1(aminoacyl tRNA 
synthetase complex-interacting multifunctional 
protein 1), ASPA (aspartoacylase) and DPP4
(dipeptidyl-peptidase 4)   because of higher 
binding affinity and specific 3D structure chose. In 
addition, both ends of the variable heavy and light 
chains of monoclonal antibody J591 as the 
antibody to PSMA antigen were explored.  
Assessment the binding affinity of ligands to the 
antigen 
By studying the connections made between ligands 
with binding epitopes involved in binding epitopes 
of PSMA was assessed on the basis of J591vL 
epitope with 197 amino acids,J591vH the epitope 
with 161 amino acids, DPP4 epitope with 44 amino 
acids, ASPA the epitope with 88 amino acids and 
AIMP1 epitope with 62 amino acids present on 
PSMA for connection altogether. 
The stable connection Compared with the level of 
minimum energy center and energy per connection 
was assessed on the basis of stable, J591vL by -
398binding energy, J591vH by-399 binding 
energy, DPP4 by  -893 binding energy, ASPA by -
788  binding energy and AIMP1 by -706  binding 
e n e r g y  l e v e l  w a s  d e t e r m i n e d . 
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Fig .2. A surface rendering in which the helical domain is light red, the apical domain is light green, the protease domain is light blue, 
and zinc ions are orange. The residues lining the substrate-binding cavity are highlighted in a darker version of the color corresponding 
to the domain from which the residue originates. 
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Fig. 3.  3D structure of PSMA ligands. A (AIMP1), B(ASPA), C(DPP4), D(J591vH), E(J591vL) 
Fig:. 4. 3D picture of  docking with PSMA and ligands . A (AIMP1),B(ASPA),C(DPP4),D(J591vH),E(J591vL) 
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Discussion: 
Cancer is a leading cause of death in the world 
(about 7.6 million people died of cancer in 2008) 
(Globocan 2008 (IACR) - globocan.iacr.fr; section 
of Cancer Information). Based on World Health 
Organization projections, in 2030, the number of 
people expected to die of cancer will be around 
11.4 million (7, 8).  
Despite the enormous amount of resources 
devoted to the area of drug development, cancer 
treatment remains one of the biggest challenges in 
public health. Many drugs have been developed to 
treat cancer. Most of them come from 
highthroughput chemical library screening and are 
designed to target specific oncogene products 
involved in cancer progression. However, after 
exposing tumor cells to those anticancer drugs, 
both toxicity and the development of resistance 
are major reasons for failure in cancer therapy. 
Therefore, new paradigms for cancer drug 
development are urgently required. It is interesting 
and somewhat surprising that bacteria may hold 
the key for finding new therapeutic approaches 
against cancer (9). Cancer therapy is often 
challenged with secondary effects caused by 
standard therapies and frequently faces tumor cell 
resistance and the inability to eliminate 
micrometastases. Therefore, new therapies are 
urgently needed. Recently, there has been 
renewed interest in the development of new 
therapeutic anticancer modalities based on the use 
of live bacteria and their purified products. 
Specific targeting of cancer cells would then allow 
the use of more cytotoxic products without 
undesired toxicity to normal tissues. Not only live 
attenuated bacterial strains have been proposed as 
anticancer agents but also products derived from 
them such as enzymes, secondary metabolites, 
proteins, or derived peptides and toxins. Bacterial 
toxins are among the most cytotoxic products in 
nature. New strategies, by genetic and protein 
engineering, offer the possibility to fuse these 
toxins with monoclonal antibodies termed 
immunotoxins, creating new powerful chimeric 
proteins that specifically target cancer cells (1, 9). 
Conventional anticancer therapeutics often suffer 
from lack of specificity, resulting in toxicities to 
normal healthy tissues and poor therapeutic index. 
Antibody-mediated delivery of anticancer drugs or 
toxins to tumor cells through tumor selective or 
overexpressed antigens is progressively being 
recognized as an effective strategy for increasing 
the therapeutic index of anticancer drugs. 
Chemotherapy remains an important and widely 
used treatment option for many types of cancers, 
but the toxic side effects often limit optimal 
dosing of anticancer drugs, thus leading to disease 
relapse, development of drug resistance and poor 
quality of life of cancer patients. Since tumor cells 
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share many common features with the normal 
cells, designing a drug that would selectively 
destroy cancer cells, bypassing normal healthy 
cells represents a major challenge of oncology drug 
development. One possible strategy to overcome 
the collateral toxicity of conventional anticancer 
agents is to harness the power of “precision-
guided” monoclonal antibodies (mAbs) that can 
deliver the drugs to the selectively-expressed or 
overexpressed antigens present on cell surface of 
malignant cells. development of a number of 
actively pursued antibody (Ab)-based technologies, 
including immunotoxins (ITs). Tumor-targeting 
ITs are chimeric molecules composed of a protein 
toxin moiety that is either chemically conjugated or 
genetically fused to mAbs or Ab fragments (10). 
Selective delivery of active agents, such as 
chemotherapeutics that are ubiquitously toxic to 
cancer cells and normal tissues, to the organs in 
question. It is ideal that those toxic chemicals are 
only delivered to tumor and/or tumor-related 
tissues to kill tumor cells with minimal side effects. 
Actively targeted drug delivery enables targeted 
and intracellular delivery of therapeutics to 
specified cells by active ligands. In addition, 
naturally aoccurring biological barriers always 
preclude the access of drug to target destinations. 
Targeted drug delivery may expedite traversal over 
such barriers. For example, gene drugs for 
intracellular targets or most of the drugs for central 
nervous system (CNS) diseases may need 
particularly targeting strategies to penetrate the 
lipid membrane of target cells and the blood–brain 
barrier (BBB), respectively. Molecularly targeted 
therapeutics block tumor growth by antagonizing 
specific targets (extracellular or intracellular) 
needed for carcinogenesis. Targeted therapy is 
expected to be more effective than conventional 
chemotherapy (11). The idea of targeted therapy, 
whereby drug or protein molecules are delivered to 
specific cells, is a compelling approach to treating 
disease. Immunotoxins are one such targeted 
therapeutic, consist-ing of an antibody domain for 
binding target cells and molecules of a toxin that 
inhibits the proliferation of the targeted cell. 
Immunotoxins are antibodies that are either 
chemically or genetically coupled to eukaryotic 
toxins. These chimeric proteins are used to deliver 
the toxin to a specific cancer cell toinitiate 
apoptosis (12). Although conventional anticancer 
therapies, consisting of surgical resection, 
radiotherapy and chemotherapy, are effective in the 
management of many patients but for about half of 
cancer sufferers these are ineffective, so alternative 
techniques are being developed to target their 
tumours. Experimental cancer treatments are 
medical therapies intended or claimed to treat 
cancer by improving, supplementing or replacing 
conventional methods. These include 
photodynamic therapy, HAMLET (human 
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alphalactalbumin made lethal to tumor cells), gene 
therapy, telomerase therapy, hyperthermia therapy, 
dichloroacetate (DCA), non-invasive RF cancer 
treatment, complementary and alternative therapy, 
diet therapy, insulin potentiating therapy and 
bacterial treatment .But many of these therapies are 
controversial due to lack of evidence, efficacy, 
feasibility, availability, specificity and selectivity 
(1). Immunotherapy for cancer offers great promise 
as an emerging and effective approach. Since 
tumors are immunogenic, the immunotherapeutic 
strategy employs stimulation of the immune 
system to destroy cancerous cells. But the major 
hurdle is the ability of tumors to escape the 
immune system due to development of tolerance as 
they are weakly immunogenic and sometimes body 
takes them as self antigens. Thus one of the novel 
immunotherapeutic strategies employs bacteria to 
enhance the antigenicity of tumor cells. Protein 
toxins such as Pseudomonas exotoxin, diphtheria 
toxin, and ricin may be useful in cancer therapy 
because they are among the most potent cell-killing 
agents. Although they are very lethal yet for 
therapeutic efficacy these toxins need to be 
targeted to specific sites on the surface of cancer 
cells. This process is accomplished by eliminating 
binding to toxin receptors by conjugating the 
toxins to cell-binding proteins such as monoclonal 
antibodies or growth factors. These conjugates 
bind and kill cancer cells selectively thus sparing 
normal cells, which don't bind the conjugates. A 
wide variety of DT ligands such as IL-3, IL-4, 
granulocyte colony stimulating factor (G-CSF), 
transferrin (Tf), EGF and vascular endothelial 
growth factor (VEGF) have been studied for 
targeted tumors. The transferrin-DT conjugate (Tf-
CRM 107) and DT-EGF have reached the stage of 
clinical trials in patients of brain tumor and 
metastatic carcinomas respectively. Similarly a 
large variety of antibodies and ligands to surface 
antigens overexpressed in different tumors have 
been conjugated to PE. Important ones tested in 
clinical trials are IL-4, IL-13, monoclonal antibody
- recognizing a carbohydrate antigen Lewis Y, 
reacting with metastatic adenocarcinoma cells 
(Mab B3) and transforming growth factor (TGF-α) 
(1). Management of unresectable or metastatic 
tumors is based on the cytotoxic effect of 
radiotherapy and/or chemotherapy. Numerous 
toxin-based therapies havebeen developed in this 
field for their potent cell-killing activity. However, 
because of the nonspecific effects of toxins on 
normal and tumor cells, targeting of cancer cells 
generally remains a prerequisite for such 
therapeutic applications. Targeting of toxins to 
cancer cells has used a variety of modalities, 
namely a direct interaction between the toxin and 
its natural receptor expressed on tumor cells; 
vectorization of the toxin by a natural ligand or a 
monoclonal antibody that specifically recognizes 
cancer cells that express their natural receptors; 
and gene therapy allowing cellular penetration of a 
viral vector expressing the toxin. In addition to 
these direct cancer cell cytotoxic approaches, a few 
publications have reported anticancer immune 
activation via T-lymphocytes, natural killer cells, 
or dendritic cells with tumor-directed targeting by 
toxin compounds.  
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Conclusion 
The most developed class of targeted cytotoxic treatments is constituted by immunotoxins. The 
immunotoxin approach is based on the use of tumor targeting ligands or antibodies that are linked to the 
catalytic moieties of bacterial or plant protein toxins. 
